Jetrea (ocriplasmin) / Oxurion 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«1234»
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Journal:  Retinal detachment after intravitreal ocriplasmin injection (Pubmed Central) -  Jan 21, 2021   
    Although retinal detachment is known as a risk factor of IVI this case is noteworthy: an excessive reaction occurred in the region of the vitreous body, which resulted in the development of severe traction on the retina leading to a posterior vitreous body detachment, retinal holes and complete retinal detachment. This possible complication should be discussed in the preoperative patient informed consent and the reason for this excessive reaction should be the subject of further investigations.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  TOTEM: Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) (clinicaltrials.gov) -  Jan 7, 2021   
    P2,  N=2, Terminated, 
    Moreover, VMT reflectivity values and ERM represented the most important parameters for the onset of vitreomacular complications. N=30 --> 2 | Trial completion date: Oct 2022 --> Jan 2021 | Recruiting --> Terminated | Trial primary completion date: Oct 2021 --> Jan 2021; Enrollment
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Biomarker, Journal:  Mutational Analysis of Ocriplasmin to Reduce Proteolytic and Autolytic Activity in Pichia pastoris. (Pubmed Central) -  Dec 17, 2020   
    The postoperative presence of posterior hyaloid shrinkage may be associated with higher traction over the foveal area and the appearance of foveolar detachment. The results indicated such variants represent valuable tools for the investigation of therapeutic strategies aiming at the non-surgical resolution of vitreomacular adhesion.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Journal:  Short-Term Results of Ocriplasmin Versus Prompt Vitrectomy for Macular Hole. Which Performs Better? (Pubmed Central) -  Dec 12, 2020   
    Although the OCRIALONE group + OCRIVIT group exhibited faster retinal thinning than the VITREALONE group (p = 0.006), the analysis of the OCRIVIT group versus the VITREALONE group did not show any statistically significant difference. The better functional results and similar anatomical findings suggest that ocriplasmin can be used as a first-line treatment, and that prompt pars plana vitrectomy as primary surgery does not provide better outcomes in comparison with pars plana vitrectomy after ocriplasmin injection.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Journal:  Cochrane Corner: Ocriplasmin-why isn't it being used more? (Pubmed Central) -  Nov 27, 2020   
    The better functional results and similar anatomical findings suggest that ocriplasmin can be used as a first-line treatment, and that prompt pars plana vitrectomy as primary surgery does not provide better outcomes in comparison with pars plana vitrectomy after ocriplasmin injection. No abstract available
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Journal:  Kringles of substrate plasminogen provide a "catalytic switch" in plasminogen to plasmin turnover by Streptokinase. (Pubmed Central) -  Oct 24, 2020   
    To understand the role of substrate plasminogen kringles in its differential catalytic processing by the streptokinase - human plasmin (SK-HPN) activator enzyme, Fluorescence Resonance Energy Transfer (FRET) model was generated between the donor labeled activator enzyme and the acceptor labeled substrate plasminogen (for both kringle rich Lys plasminogen - LysPG, and kringle less microplasminogen - µPG as substrates)...Remarkably, active site titration studies and the kinetics of peptide bond cleavage have shown that post docking chemical transformation of the substrate into the product is independent of kringles adjacent to the catalytic domain. Stopped-flow based rapid mixing experiments for kringle rich and kringle less substrate plasminogen derivatives under substrate saturating and single-cycle turn-over conditions have shown that the presence of kringle domains adjacent to the catalytic domain in the macromolecular substrate contributes by selectively speeding up the final step, namely the product release/expulsion step of catalysis by the streptokinase-plasmin(ogen) activator enzyme.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    [VIRTUAL] Atypical Presentation of an Epiretinal Membrane with Significant Retinal Traction (Track 1 - Academy at Home) -  Oct 14, 2020 - Abstract #AAOPT2020AAOPT_904;    
    The remnant layer may stimulate migration of glial cells from the circulation to the retina and induce puckering and tangential traction upon the underlying retina.1,2An epiretinal membrane may occur due to changes at the vitreoretinal interface from trauma, uveitis, retinal detachments, retinal vascular diseases, retinal surgeries, or it may be idiopathic in etiology.1,2 Treatment, Management Equal visual acuities and no other pertinent differences between eyes suggested the extensive epiretinal membrane with significant traction was not severely visually significant OD.Thus, the patient was advised to return to clinic for monitoring every 6 months with DFE given the relative stability of OCT imaging vs 2015, peripheral location of epiretinal membrane and no changes to acuity or symptoms.Treatment options may include pars plana vitrectomy with consideration of a macular peel to improve visual acuity and decrease metamorphopsia. However, risks may include accelerated cataract formation, retinal breaks or detachments, and macular edema.3 Although there may be visual recovery in up to 80% of patients who undergo a vitrectomy, eyes may still show persistent retinal thickening.4,6Additional treatment may include Ocriplasmin, a recombinant proteolytic enzyme used as an intravitreal injection for pharmacological vitreolysis.5, Conclusion OCT is a useful diagnostic tool to help examine the vitreoretinal interface and possible consequences of vitreoretinal traction.Although visual dysfunction for peripherally located epiretinal membranes may not be significant, it is important for clinicians to give a guarded prognosis and continue to monitor closely for risk of vision loss.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    [VIRTUAL] Combined Pneumatic and Enzymatic Vitreolysis for Severe Cases of Vitreomacular Traction () -  Sep 15, 2020 - Abstract #RSLONDON2020RS_LONDON_290;    
    We analyzed a retrospective, consecutive series of five patients diagnosed with severe VMT refractory to pneumatic vitreolysis (PV) who then received an additional ocriplasmin injection while their gas bubble from PV was still present between February 2015 to February 2019... Sequential, combined pneumatic and enzymatic vitreolysis resulted in VMT release in of all 5 cases (4 cases by 28 days) and may be a potentially useful alternative to surgical intervention for refractory VMT cases.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Retrospective data, Journal:  SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND VISUAL OUTCOME AFTER TREATMENT FOR VITREOMACULAR TRACTION. (Pubmed Central) -  Aug 5, 2020   
    Recovery of the COST line and inner segment/outer segment line defects as observed by spectral domain optical coherence tomography is positively correlated with visual acuity improvement after successful vitreomacular traction treatment. Best-corrected visual acuity improvement may be predicted using the length of the preoperative COST line defect.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Intravitreal Injections in Arc Sterile Setting: Safety Profile after More Than 10,000 Treatments. (Pubmed Central) -  May 8, 2020   
    The residents performed over 80% of IVIs, but there was no statistically significant difference in incidence of complications between the residents group and consultants group. Arc Sterile seems to be a safe setting in which IVIs can be carried out, regarding infective risk, and it is easy to set up compared to operation theatre and useful to improve intravitreal injections governance.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Comparison of enzymatic vitreolysis (EVL) and pneumatic vitreolysis (PVL) for symptomatic vitreomacular traction (sVMT) (Exhibit Hall: Posterboard# A0360) -  Mar 9, 2020 - Abstract #ARVO2020ARVO_4375;    
    All patients fulfilled the British National Institute for Clinical Excellence(NICE) guidelines for treatment with ocriplasmin...Novel PVL treatment appears to be a more effective and cheaper option than EVL in this cohort of patients, with fewer patients requiring subsequent vitrectomy. Further prospective studies with larger groups of patients over a longer period will help to fully evaluate above observations.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Biomarker, Journal:  THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters. (Pubmed Central) -  Mar 3, 2020   
    Substudy results suggest that fixation and sensitivity parameters tended to be better in the ocriplasmin group than in the sham group over time. The substudy identified parameters that were distinct between patients with and without vitreomacular adhesion resolution, suggesting that microperimetry warrants further study as a relevant biomarker for visual function.
  • ||||||||||  Jetrea (ocriplasmin) / Oxurion
    Journal:  Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition. (Pubmed Central) -  Feb 9, 2020   
    Thus, the present study successfully identifies single- and double-site PEGylated muteins of microplasmin with significantly enhanced functional half-life through enhanced resistance to inactivation by its in vivo plasma inhibitor. Such an increased survival of bioactivity in situ, holds unmistakable potential for therapeutic exploitation, especially in ischemic strokes where a direct, catheter-based deposition within the cranium has been shown to be promising, but is currently limited by the very short in vivo bioactive half-life of the fibrin dissolving agent/s.
  • ||||||||||  Jetrea (ocriplasmin) / Thrombogenics
    Journal:  Pharmacotherapy of vitreomacular traction. (Pubmed Central) -  Nov 23, 2019   
    Many agents have been investigated and trialled including plasmin, microplasmin (Ocriplasmin), hyaluronidase, nattokinase, chondroitinase and dispase. This review will focus on the progress and current status in this research.
  • ||||||||||  Jetrea (ocriplasmin) / Thrombogenics
    Clinical, Journal:  Efficacy and Safety Profile of Ocriplasmin Treatment - an Update (Pubmed Central) -  Oct 9, 2019   
    Structural outer retinal layer changes, such as ellipsoid zone disturbances or subretinal fluid accumulation on SD-OCT analysis, as well as ERG abnormalities, are transient and correlated to VMT release. Surgical outcomes in patients with a prior history of ocriplasmin injection have been shown to be comparable with patients who proceeded directly to surgery without ocriplasmin treatment.
  • ||||||||||  Jetrea (ocriplasmin) / Thrombogenics, Ozurdex (dexamethasone intravitreal implant) / Allergan
    Therapy of intravitreal medical therapy-associated retinal detachment (Room: 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2071;    
    Despite the low numbers of cases, we have noticed that re-RD occurs with a higher incidence after dexamethasone. The most common absolute diagnosis for IVARD was ocular vein occlusion.
  • ||||||||||  Jetrea (ocriplasmin) / Thrombogenics
    Effectiveness of ocriplasmin in real-world settings and clinical trials: a systematic literature review (Room: 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2066;    
    VMAR rates are higher in MH patients treated in RWS than in those treated in RCTs, while vitrectomy rates in RWS are lower. The limitations of this analysis include the absence of patient-level information on important treatment-modifying baseline factors (VMA width, ERM status and age) for RWS studies, the lack of a common evaluation time point and the retrospective, non-randomized nature of this comparison.
  • ||||||||||  Jetrea (ocriplasmin) / Thrombogenics, Ozurdex (dexamethasone intravitreal implant) / Allergan
    Therapy of intravitreal medical therapy-associated retinal detachment (Room 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1821;    
    Despite the low numbers of cases, we have noticed that re-RD occurs with a higher incidence after dexamethasone. The most common absolute diagnosis for IVARD was ocular vein occlusion.
  • ||||||||||  Jetrea (ocriplasmin) / Thrombogenics
    Effectiveness of ocriplasmin in real-world settings and clinical trials: a systematic literature review (Room 241) -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1816;    
    VMAR rates are higher in MH patients treated in RWS than in those treated in RCTs, while vitrectomy rates in RWS are lower. The limitations of this analysis include the absence of patient-level information on important treatment-modifying baseline factors (VMA width, ERM status and age) for RWS studies, the lack of a common evaluation time point and the retrospective, non-randomized nature of this comparison.